UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions

European urology, 2019-01, Vol.75 (1), p.100-110

2019

Volltextzugriff (PDF)

Metabolomic adaptations and correlates of survival to immune checkpoint blockade

Nature communications, 2019-09, Vol.10 (1), p.4346-6, Article 4346

2019

Volltextzugriff (PDF)

Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma

European journal of cancer (1990), 2020-08, Vol.135, p.203-210

2020

Volltextzugriff (PDF)

Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma

Journal for immunotherapy of cancer, 2018-01, Vol.6 (1), p.5-5, Article 5

2018

Volltextzugriff (PDF)

The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma

Human vaccines & immunotherapeutics, 2023-12, Vol.19 (1), p.2178217-2178217

2023

Volltextzugriff (PDF)

Pan-urologic cancer genomic subtypes that transcend tissue of origin

Nature communications, 2017-08, Vol.8 (1), p.199-15, Article 199

2017

Volltextzugriff (PDF)

Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review

Therapeutic Advances in Medical Oncology, 2022, Vol.14, p.17588359221108685-17588359221108685

2022

Volltextzugriff (PDF)

Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

Cancer medicine (Malden, MA), 2021-02, Vol.10 (4), p.1212-1221

2021

Volltextzugriff (PDF)

Next Wave of Targets in the Treatment of Advanced Renal Cell Carcinoma

Current oncology (Toronto), 2022-07, Vol.29 (8), p.5426-5441

2022

Volltextzugriff (PDF)

Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events

Cancer immunology research, 2018-04, Vol.6 (4), p.402-408

2018

Volltextzugriff (PDF)

Genomic and Clinical Correlates of Adrenocortical Carcinoma in an Adult Patient with Li-Fraumeni Syndrome: A Case Report

Current oncology (Toronto), 2020-12, Vol.28 (1), p.226-232

2020

Volltextzugriff (PDF)

Evaluating the impact of early identification of asymptomatic brain metastases in metastatic renal cell carcinoma

Cancer reports, 2023-03, Vol.6 (3), p.e1763-n/a

2023

Volltextzugriff (PDF)

Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series

Journal for immunotherapy of cancer, 2017-08, Vol.5 (1), p.66-66, Article 66

2017

Volltextzugriff (PDF)

Trends of Utilization of Systemic Therapies for Metastatic Renal Cell Carcinoma in the Canadian Health Care System

JCO global oncology, 2023-09, Vol.9 (9), p.e2300271-e2300271

2023

Volltextzugriff (PDF)

Optimizing Treatment Selection in Advanced Renal Cell Carcinoma via IMDC Risk Group Stratification

European urology, 2023-10, Vol.84 (4), p.379-380

2023

Volltextzugriff (PDF)

Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study

European urology, 2024-07, Vol.86 (1), p.4-9

2024

Volltextzugriff (PDF)

Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial

Clinical cancer research, 2022-02, Vol.28 (4), p.738-747

2022

Volltextzugriff (PDF)

Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts

JCO global oncology, 2020-11, Vol.6 (6), p.293-306

2020

Volltextzugriff (PDF)

Response of Primary Renal Cell Carcinoma to Systemic Therapy

European urology, 2019-12, Vol.76 (6), p.852-860

2019

Volltextzugriff (PDF)

Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma

British journal of cancer, 2018-09, Vol.119 (6), p.707-712

2018

Volltextzugriff (PDF)

Systemic treatments for metastatic urothelial carcinoma

Expert opinion on pharmacotherapy, 2019-01, Vol.20 (2), p.201-208

2019

Volltextzugriff (PDF)

The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma

Cancer immunology research, 2018-07, Vol.6 (7), p.758-765

2018

Volltextzugriff (PDF)

Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma

British journal of cancer, 2018-05, Vol.118 (9), p.1238-1242

2018

Volltextzugriff (PDF)

Proton pump inhibitors and survival outcomes in patients with metastatic renal cell carcinoma

Clinical genitourinary cancer, 2017-12, Vol.15 (6), p.724-732

2017

Volltextzugriff (PDF)

1 – 25 von 127

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(124)
Mit Volltextzugriff
(105)

Publikationsform

Artikel
(127)

Sprache

Englisch
(127)

Erscheinungsjahr

n.n

Thema

Science & Technology
(67)
Life Sciences & Biomedicine
(65)
Oncology
(39)
Urology & Nephrology
(34)
Humans
(32)
Immunotherapy
(22)
Renal Cell Carcinoma
(18)
Kidney Neoplasms - Drug Therapy
(15)
Carcinoma, Renal Cell - Drug Therapy
(14)
Metastasis
(14)
Male
(13)
Middle Aged
(13)
Treatment Outcome
(13)
Aged
(12)
Kidney Neoplasms - Pathology
(12)
Female
(11)
Kidney Cancer
(11)
Care And Treatment
(10)
Bladder Cancer
(9)
Cancer
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions

Metabolomic adaptations and correlates of survival to immune checkpoint blockade

Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma

Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma

The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma

Pan-urologic cancer genomic subtypes that transcend tissue of origin

Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review

Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

Next Wave of Targets in the Treatment of Advanced Renal Cell Carcinoma

Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events

Genomic and Clinical Correlates of Adrenocortical Carcinoma in an Adult Patient with Li-Fraumeni Syndrome: A Case Report

Evaluating the impact of early identification of asymptomatic brain metastases in metastatic renal cell carcinoma

Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series

Trends of Utilization of Systemic Therapies for Metastatic Renal Cell Carcinoma in the Canadian Health Care System

Optimizing Treatment Selection in Advanced Renal Cell Carcinoma via IMDC Risk Group Stratification

Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study

Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial

Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts

Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

Response of Primary Renal Cell Carcinoma to Systemic Therapy

Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma

Systemic treatments for metastatic urothelial carcinoma

The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma

Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma

Proton pump inhibitors and survival outcomes in patients with metastatic renal cell carcinoma

Suchergebnisse filtern